DNMT1 and neoplasm: Growing preclinical and clinical evidence suggests that hypomethylating agents can induce DNA demethylation and ERV reactivation, resulting in a viral mimicry state to generate anti-tumor immune responses.18,37 However, the expression of DNMT1 showed no significant difference between TP53mut and TP53wt DLBCL patients and cell lines.